Oral Thalidomide and Tegafur-uracil to Decrease Hepatocellular Carcinoma Recurrence
Status:
Completed
Trial end date:
2017-02-02
Target enrollment:
Participant gender:
Summary
This single-centered phase II clinical study is to obtain preliminary information on 1-year
recurrence-free survival rate, recurrence-free survival and safety profile of thalidomide in
combination with tegafur-uracil in hepatocellular carcinoma after hepatectomy and explore
biomarkers(VEGF/bFGF) for thalidomide response.